GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Cash Flow for Lease Financing

Transgene (XPAR:TNG) Cash Flow for Lease Financing : €-1.19 Mil (TTM As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Transgene Cash Flow for Lease Financing?

Transgene's Cash Flow for Lease Financing for the six months ended in Dec. 2023 was €-0.58 Mil. Transgene's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.19 Mil.

Compared with last quarter (€-0.61 Mil in Jun. 2023 ), Transgene's Cash Flow for Lease Financing increased in Dec. 2023 (€-0.58 Mil).

Transgene Cash Flow for Lease Financing Historical Data

The historical data trend for Transgene's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Cash Flow for Lease Financing Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.23 -1.51 -1.28 -1.28 -1.19

Transgene Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.65 -0.64 -0.64 -0.61 -0.58

Transgene Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Transgene's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene (XPAR:TNG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Cash Flow for Lease Financing
Comparable Companies
XPAR:ADOC XPAR:DBV XPAR:MAAT XPAR:IVA XPAR:AELIS XPAR:OSE XPAR:ALVAL XPAR:GNFT XPAR:GNRO XPAR:IPH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TGNA:Germany
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400
Website
https://www.transgene.fr
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines